# Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

> clinical trial · VERIFIED · 2026-06-16

Status: ACTIVE_NOT_RECRUITING · Sponsor: Cardiff Oncology · Condition: Metastatic Colorectal Cancer

- Company: Cardiff Oncology
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06106308

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.